Correlation Network (CN), established in 2004, developed to the largest network on Health and Social Inclusion in Europe with currently more than 180 members in 32 European countries. The aim of the Network is to link various expertise and experiences to enhance outcomes and impact by combining practice, research and policy. In the last decade, C N has fostered numerous health and social collaborations, developed interventions, guiding documents, capacity building events and conferences.
CN is hosted by the Regenboog Groep in the Netherlands. In 2013, it established the 'Hepatitis C Initiative' with financial support of the European Union Drug Prevention and Information programme (DPIP) the first pan European collaboration on HCV and drug use.
In 2015, CN received funds from GILEAD and Abbvie to maintain the Initiative and to launch certain activities.
The Hepatitis Initiative is coordinated by the Correlation Network coordinators.
Resource Centre and trainings
A selected Advisory Board, external experts and a broad range of partners support the work of the Initiative.
The AB is responsible for:
- developing the network strategy and future priorities;
- advising the CO in the development and implementation of projects and activities;
- representing the network and its mission and activities on national and European levels. The operational rules and procedures of the AB are stipulated in the Terms of Reference (ToR), which describes the role of the AB, the membership and structure of the AB, the rights and responsibilities and the principles of interaction between AB and CO.
Members of the 2016 Advisory Board:
Prof Magdalena Harris, London School of Hygiene and Tropical Medicine, London
John Peter Kools, president Harm Reduction International (HRI), Amsterdam
Prof Jeff Lazarus, CHIP, University of Copenhagen, Copenhagen
Astrid Leicht, director Fixpunkt, Berlin
Tony van Montfort, European Network of People Who Use Drugs (EuroNPUD), Antwerp
The Correlation Hepatitis C Initaitive was build 2013 – 2014 with support of a grant of the European Commission's Drug Prevention and Information Programme (DPIP).
The Correlation Hepatitis C Initiative 2016 is supported by an unrestricted grant from Gilead Science Europe Ltd.
The training activities of the Correlation Hepatitis C Initiative are supported by an grant of AbbVIe Biopharmaceuticals Sarl.
The Parties undertakes to strictly abide by the Regulations and the “European Federation of Pharmaceutical Industries and Associations (“EFPIA”) Code of practice on relationships between the pharmaceutical industry and patient organizations” (the “EFPIA Code”), as well as the Code of Deontoloy (“Code de déontologie/code voor deontologie) of pharma.be, as amended from time to time.